Stacy and NYT journalist Susan Dominus pick up where Part 1 left off — this time going deep on the hormone that's barely made it into the mainstream menopause conversation: testosterone. Susan, who recently reported an in-depth piece on testosterone for women, breaks down what the research actually shows, why the US is so far behind other countries, and what happens when women go far beyond the studied dose. They get into the delivery problem — why there's no FDA-approved option for women yet, the proposal for a testosterone pill, the risks and side effects at high doses, and how telehealth is filling the gap with varying degrees of rigor.From there, the conversation expands: GLP-1s and their surprising reach beyond weight loss, what longevity researchers actually say is the number one predictor of a longer life, and a fascinating new field called cellular rejuvenation that may one day reverse aging at the cellular level. Hello Menopause is a podcast from Let’s Talk Menopause. Produced in partnership with Studio Kairos. Supervising Producer: Kirsten Cluthe. Artwork by Stacey Geller. Subscribe to Hello Menopause on YouTube, Apple Podcasts, Spotify, or wherever you get your podcasts. And if you loved this conversation, leave us a review and share it with your community. Visit LetsTalkMenopause.org for menopause resources, expert Q&As, and a symptom checklist. Learn more about your ad choices. Visit megaphone.fm/adchoices

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related